Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31228374 | 0.96 | P2RX7 (0.42) | P2RX7L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL31228552 | 0.91 | P2RX7 (0.42) | P2RX7L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL31228239 | 0.89 | MMP13 (0.39) | P2RX7HCRTR2L3MBTL1MEN1KMT2A | |
| SCHEMBL31228393 | 0.86 | KLK7 (0.44) | KLK7HCRTR2L3MBTL1MEN1KMT2A | |
| SCHEMBL31228678 | 0.85 | MMP13 (0.37) | P2RX7HCRTR2MEN1KMT2A | |
| SCHEMBL31228300 | 0.85 | MMP13 (0.40) | P2RX7HCRTR2MEN1KMT2A | |
| SCHEMBL31228306 | 0.85 | MMP13 (0.40) | P2RX7HCRTR2MEN1KMT2A | |
| SCHEMBL31228513 | 0.83 | P2RX7 (0.44) | P2RX7L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL31228745 | 0.82 | KLK7 (0.39) | KLK7HCRTR2L3MBTL1MEN1KMT2A | |
| SCHEMBL31228368 | 0.81 | MAPT (0.40) | KLK7L3MBTL1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211663-A9 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024211663-A1 | CONDENSED MACROCYCLIC COMPOUNDS AS RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-10-10 | — | — | WO | disclosed |